Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Ya'nan Ren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou563000, China. Hauptthemen laut MEDLINE: Zirconium, Urinary Bladder Neoplasms, Antibodies, Monoclonal, Radioisotopes. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Guizhou Provincial Basic Research Program, National Natural Science Foundation of China, Zunyi Science and Technology Cooperation Project.
Abstract (Originalsprache)
This study evaluated the preclinical performance of a novel 89Zr-labeled anti-Nectin-4 monoclonal antibody, [89Zr]Zr-DFO-MW282, for PET imaging of bladder urothelial carcinoma (BUC). [89Zr]Zr-DFO-MW282 was prepared via p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bn-DFO) conjugation, achieving a radiolabeling yield exceeding 70%, radiochemical purity ≥95% post-purification, and specific activity of 36.10−63.72 GBq/μmol. [89Zr]Zr-DFO-MW282 selectively accumulated in Nectin-4-positive cells and tumors, with uptake blocked by the unlabeled MW282 antibody. Small-animal PET/CT imaging revealed sustained tumor uptake in SW780 xenografts, with a high SUVmean value of 4.46 ± 0.02 at 120 h p.i. Owing to hepatobiliary clearance, the kidney and bladder uptake was minimal, yielding excellent imaging contrast. The probe demonstrated high specificity, prolonged tumor retention, and negligible bladder background, making it a promising immuno-PET probe for precise imaging of BUC and warranting further clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou563000, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of N…
Förderung
- Guizhou Provincial Basic Research Program
- National Natural Science Foundation of China
- Zunyi Science and Technology Cooperation Project
Zitieren
APA
Ren, Y., Liu, T., Hou, X., Yao, Y., Wang, P., Xia, L., Liu, S., Wang, P., Cai, J., Pan, D., Zhu, H., & Yang, Z. (2026). Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01979
Vancouver
Ren Y, Liu T, Hou X, Yao Y, Wang P, Xia L, et al. Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01979
BibTeX
@article{Ren2026,
author = {Ren, Ya'nan and Liu, Teli and Hou, Xingguo and Yao, Yuan and Wang, Pei and Xia, Lei and Liu, Song and Wang, Pan and Cai, Jiong and Pan, Dongfeng and Zhu, Hua and Yang, Zhi},
title = {Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01979}
}
EUVIMED